Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting.

Krambeck AE, Jacobson DJ, McGree ME, Lightner DJ, Lieber MM, Jacobsen SJ, St Sauver JL.

BJU Int. 2012 Nov;110(9):1332-7. doi: 10.1111/j.1464-410X.2012.10998.x. Epub 2012 Apr 3.

2.

Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes.

Mayer EK, Kroeze SG, Chopra S, Bottle A, Patel A.

BJU Int. 2012 Dec;110(11):1595-601. doi: 10.1111/j.1464-410X.2012.11119.x. Epub 2012 Apr 30. Review.

3.

GreenLight HPS™ 120-W laser vaporization vs transurethral resection of the prostate (<60 mL): a 2-year randomized double-blind prospective urodynamic investigation.

Pereira-Correia JA, de Moraes Sousa KD, Santos JB, de Morais Perpétuo D, Lopes-da-Silva LF, Krambeck RL, Muller VJ, Vaz FP.

BJU Int. 2012 Oct;110(8):1184-9. doi: 10.1111/j.1464-410X.2011.10878.x. Epub 2012 Jan 18.

4.

Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.

Ingimarsson JP, Isaksson HJ, Sigbjarnarson HP, Gudmundsson J, Geirsson G.

Scand J Urol. 2014 Feb;48(1):73-8. doi: 10.3109/21681805.2013.825878. Epub 2013 Aug 7.

PMID:
23924152
5.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ; European Association of Urology.

Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13. Review.

PMID:
23541338
6.

[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].

Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi AR, Faix A, Desgrandchamps F, de la Taille A; Comité des troubles mictionnels de l’homme de l’association française d’urologie.

Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. French.

PMID:
23178093
7.

Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.

Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.

BJU Int. 2012 Dec;110(11 Pt C):E837-44. doi: 10.1111/j.1464-410X.2012.11288.x. Epub 2012 Jun 19.

8.

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.

MacDonald R, Tacklind JW, Rutks I, Wilt TJ.

BJU Int. 2012 Jun;109(12):1756-61. doi: 10.1111/j.1464-410X.2012.11172.x. Epub 2012 May 2. Review.

10.

Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).

Elshal AM, Elmansy HM, Elhilali MM.

BJU Int. 2012 Dec;110(11 Pt C):E845-50. doi: 10.1111/j.1464-410X.2012.11290.x. Epub 2012 Jun 15.

11.

Transurethral resection of prostate with plasmakinetic energy: 100 months results of a prospective randomized trial.

Muslumanoglu AY, Yuruk E, Binbay M, Akman T.

BJU Int. 2012 Aug;110(4):546-9. doi: 10.1111/j.1464-410X.2011.10770.x. Epub 2011 Nov 24.

12.

GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up.

Capitán C, Blázquez C, Martin MD, Hernández V, de la Peña E, Llorente C.

Eur Urol. 2011 Oct;60(4):734-9. doi: 10.1016/j.eururo.2011.05.043. Epub 2011 Jun 1.

PMID:
21658839
13.

Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

Fourcade RO, Lacoin F, Rouprêt M, Slama A, Le Fur C, Michel E, Sitbon A, Cotté FE.

World J Urol. 2012 Jun;30(3):419-26. doi: 10.1007/s00345-011-0756-2. Epub 2011 Sep 3.

14.

Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.

Fukuta F, Masumori N, Mori M, Tsukamoto T.

BJU Int. 2012 Oct;110(7):1023-9. doi: 10.1111/j.1464-410X.2011.10866.x. Epub 2012 Jan 11.

15.

Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia.

Fowler C, McAllister W, Plail R, Karim O, Yang Q.

Health Technol Assess. 2005 Feb;9(4):iii-iv, 1-30. Review.

16.

A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia.

Cowles RS 3rd, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B, Zabbo A.

Urology. 1995 Aug;46(2):155-60.

PMID:
7542818
17.

Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome.

Bachmann A, Schürch L, Ruszat R, Wyler SF, Seifert HH, Müller A, Lehmann K, Sulser T.

Eur Urol. 2005 Dec;48(6):965-71; discussion 972. Epub 2005 Jul 18.

PMID:
16126327
18.

Microwave thermotherapy for benign prostatic hyperplasia.

Hoffman RM, Monga M, Elliot SP, Macdonald R, Wilt TJ.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004135. Review. Update in: Cochrane Database Syst Rev. 2012;9:CD004135.

PMID:
17943811
19.

Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.

Liatsikos E, Kyriazis I, Kallidonis P, Stolzenburg JU.

Aging Male. 2011 Sep;14(3):141-9. doi: 10.3109/13685538.2010.548881. Epub 2011 Jan 19. Review.

PMID:
21247241
20.

The use of generic measures of health-related quality of life in the assessment of outcome from transurethral resection of the prostate.

MacDonagh RP, Cliff AM, Speakman MJ, O'Boyle PJ, Ewings P, Gudex C.

Br J Urol. 1997 Mar;79(3):401-8.

PMID:
9117222
Items per page

Supplemental Content

Write to the Help Desk